The Grey Zone Project: Risk‐Based Classification of ABCD1 Variants in X‐Linked Adrenoleukodystrophy
Journal of Inherited Metabolic Disease · 2026-03 · 49 (2)
DOI: 10.1002/jimd.70157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.02.2026. Verfasst von Troy C Lund und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Pediatric Blood and Marrow Transplantation and Cellular Therapy, University of Minnesota Medical School, Minneapolis, Minne…. Hauptthemen laut MEDLINE: Adrenoleukodystrophy, ATP Binding Cassette Transporter, Subfamily D, Member 1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting Metakids, ALD Connect, Virginia B. Toulmin Foundation.
Abstract (Originalsprache)
Newborn screening (NBS) for X‐linked adrenoleukodystrophy (ALD) enables early identification of boys at risk for adrenal insufficiency (AI) and cerebral ALD (CALD). However, NBS frequently identifies ABCD1 variants of uncertain significance (VUS), which are associated with only borderline‐elevated C26:0‐lysophosphatidylcholine (LPC(26:0)) levels. Traditional American College of Medical Genetics and Genomics (ACMG) pathogenicity classification does not account for age‐dependent penetrance or the broader phenotypic spectrum, complicating risk assessment and clinical management. Through the Grey Zone Project, we developed a risk‐stratification framework using a receiver operating characteristic (ROC)‐based approach prioritizing 95% sensitivity. This framework incorporates biochemical and longitudinal clinical data from 1627 control subjects and 196 confirmed ALD patients. Three pediatric risk categories were defined: “no ALD” (177 nmol/L). When applied to 108 samples carrying 51 unique ABCD1 VUSs, 26 variants were reclassified as “no ALD,” 15 as “lower‐risk AI/CALD,” and 10 as “at‐risk AI/CALD.” The framework reclassifies ABCD1 variants based on biochemical risk profiles, reducing false‐positive referrals, avoiding unnecessary MRI surveillance, and alleviating parental anxiety by identifying children who are unlikely to develop childhood‐onset disease. Integrating biochemical thresholds with genetic and longitudinal clinical data improves the specificity of NBS without compromising its sensitivity. Providing systematic feedback on false‐positive cases to screening laboratories will further refine cut‐offs. This framework provides a scalable, evidence‐based model for interpreting variants and enabling personalized follow‐up in ALD and other disorders with a variable age of onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Pediatric Blood and Marrow Transplantation and Cellular Therapy, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- ALD Connect (https://aldconnect.org/), Middleton, Massachusetts, USA.
- Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Neurology, University Medical Center, Leipzig, Germany.
- Center for Personalized Medicine, Primary Children's Hospital, Division of Pediatric Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
- Center for Diagnosis and Treatment of Leukodystrophies and Genetic Leukoencephalopathies (COALA), Vittore Buzzi Children's Hospital, Milan, Italy.
ORCID-Profile: Fabio Bruschi, Mirjam M C Wamelink, Stephan Kemp
Förderung
- Stichting Metakids
- ALD Connect
- Virginia B. Toulmin Foundation
Zitieren
APA
Lund, T. C., Miettunen, K., Jaspers, Y. R. J., Bergner, C., Bonkowsky, J. L., Bruschi, F., Cohen, J. S., Dijkstra, I. M. E., Eichler, F. S., Mallack, E. J., Salomons, G. S., Thompson, R., Tonduti, D., van Haren, K. P., Wamelink, M. M. C., Zerem, A., Engelen, M., & Kemp, S. (2026). The Grey Zone Project: Risk‐Based Classification of ABCD1 Variants in X‐Linked Adrenoleukodystrophy. Journal of Inherited Metabolic Disease, 49(2). https://doi.org/10.1002/jimd.70157
Vancouver
Lund TC, Miettunen K, Jaspers YRJ, Bergner C, Bonkowsky JL, Bruschi F, et al. The Grey Zone Project: Risk‐Based Classification of ABCD1 Variants in X‐Linked Adrenoleukodystrophy. Journal of Inherited Metabolic Disease. 2026;49(2). doi:10.1002/jimd.70157
BibTeX
@article{Lund2026,
author = {Lund, Troy C and Miettunen, Kelly and Jaspers, Yorrick R J and Bergner, Caroline and Bonkowsky, Joshua L and Bruschi, Fabio and Cohen, Julie S and Dijkstra, Inge M E and Eichler, Florian S and Mallack, Eric J and Salomons, Gajja S and Thompson, Robert and Tonduti, Davide and van Haren, Keith P and Wamelink, Mirjam M C and Zerem, Ayelet and Engelen, Marc and Kemp, Stephan},
title = {The Grey Zone Project: Risk‐Based Classification of ABCD1 Variants in X‐Linked Adrenoleukodystrophy},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {2},
doi = {10.1002/jimd.70157}
}
EUVIMED